Jeff S Matsler
Jeff Matsler is the Regional Director of Ethics at CHRISTUS Santa Rosa and Children's Hospital of San Antonio where he oversees the Ethics Program for the 6 hospital regional system. Previously, he was a Clinical Ethicist at Wellstar Health System in the Greater Atlanta area and - prior to miilitary retirement - was Bioethicist for the United States Army.
Jeff is a PhD student at Duquesne University, with a focus on moral injury in combat veterans. He teaches Healthcare Ethics at St. Mary’s University in San Antonio, Texas and in Yale University's Summer Bioethics Program in New Haven Connecticut. Jeff is also an Adjunct Professor at Africa University in Harare, Zimbabwe and an Adjunct Instructor of Ethics at The Uniformed Services University of Health Sciences in Bethesda, Maryland.
Supervisors: Sarah Hill, VP of Missions
Phone: 806-681-4663
Address: San Antonio, Texas
Jeff is a PhD student at Duquesne University, with a focus on moral injury in combat veterans. He teaches Healthcare Ethics at St. Mary’s University in San Antonio, Texas and in Yale University's Summer Bioethics Program in New Haven Connecticut. Jeff is also an Adjunct Professor at Africa University in Harare, Zimbabwe and an Adjunct Instructor of Ethics at The Uniformed Services University of Health Sciences in Bethesda, Maryland.
Supervisors: Sarah Hill, VP of Missions
Phone: 806-681-4663
Address: San Antonio, Texas
less
Related Authors
InterestsView All (13)
Uploads
Papers by Jeff S Matsler
"In society’s quest for scientific gains, particularly when conducting medical research, it is imperative our ethical standards are never sacrificed on the altar of knowledge. This is particularly true for research conducted with human participants—and exponentially so for individuals who lack the ability to consent for themselves—a category of individuals which includes, among others, children (FDA2019a). This intentional ethical restraint in human subjects research makes it particularly complicated to think about conducting research for diseases that either only
occur in youth or those, such as Pediatric Systemic Lupus Erythematosus (pSLE), that manifest and
exhibit differently and with different mortality/morbidity rates than when onset occurs in adulthood
(Weiss2012). In these instances it becomes necessary to determine which is the lesser harm: not learning about the potential treatments designed specifically to counter the progress of a disease and its unique progression in younger participants; or taking limited,controlled risk (even if greater than minimal) in an effort to benefit those currently suffering and potentially ease that of those who may encounter the condition in the future. The FDA has very specific guidelines which restrict and/or allow research with children in studies that impose greater than minimal risk upon its participants, which are listed in the “Common Rule,”specifically in 21 CFR 50 Subpart D (FDA2019a)."
The online edition is available on the publisher's site at https://www.christianitytoday.com/ct/2015/june/formed-by-war-ptsd.html.
"In society’s quest for scientific gains, particularly when conducting medical research, it is imperative our ethical standards are never sacrificed on the altar of knowledge. This is particularly true for research conducted with human participants—and exponentially so for individuals who lack the ability to consent for themselves—a category of individuals which includes, among others, children (FDA2019a). This intentional ethical restraint in human subjects research makes it particularly complicated to think about conducting research for diseases that either only
occur in youth or those, such as Pediatric Systemic Lupus Erythematosus (pSLE), that manifest and
exhibit differently and with different mortality/morbidity rates than when onset occurs in adulthood
(Weiss2012). In these instances it becomes necessary to determine which is the lesser harm: not learning about the potential treatments designed specifically to counter the progress of a disease and its unique progression in younger participants; or taking limited,controlled risk (even if greater than minimal) in an effort to benefit those currently suffering and potentially ease that of those who may encounter the condition in the future. The FDA has very specific guidelines which restrict and/or allow research with children in studies that impose greater than minimal risk upon its participants, which are listed in the “Common Rule,”specifically in 21 CFR 50 Subpart D (FDA2019a)."
The online edition is available on the publisher's site at https://www.christianitytoday.com/ct/2015/june/formed-by-war-ptsd.html.